<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02138734</url>
  </required_header>
  <id_info>
    <org_study_id>CA-ALT-803-01-14; QUILT-2.005</org_study_id>
    <nct_id>NCT02138734</nct_id>
  </id_info>
  <brief_title>A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer</brief_title>
  <official_title>A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altor BioScience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Altor BioScience</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase Ib/IIb, randomized, two-cohort, open-label, multicenter study of intravesical
      ALT-803 plus BCG versus BCG alone, in BCG naïve patients with high-grade NMIBC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study includes a dose escalation phase (phase Ib) and an expansion phase (phase IIb).

      In the phase Ib, patients will be treated with intravesical ALT-803 in combination with BCG.
      The purpose of the phase Ib portion of the study is to evaluate the safety, identify the
      Maximum Tolerated Dose (MTD) of ALT-803 and determine the Recommended Dose (RD) level of
      ALT-803 in combination with BCG for the phase IIb expansion.

      In the phase IIb expansion, patients will be randomized to receive either intravesical
      ALT-803 in combination with BCG or BCG alone. Patients will be enrolled into one of two study
      cohorts (Cohort A and Cohort B). These will be two independent study cohorts, evaluated
      separately for treatment efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2014</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single arm phase Ib.
Two-arm phase IIb, two-cohort: each randomized 1:1 via randomization scheme stratified by disease and ECOG status.
Cohort A: patients with CIS disease (with or without Ta/T1); planned enrollment = 366 Cohort B: patients with high-grade papillary disease (Ta/T1 only); planned enrollment = 230</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response (CR) Rate</measure>
    <time_frame>12 months</time_frame>
    <description>For phase IIb patients in Cohort A: compare complete response rate between treatment arms using cystoscopy, confirmatory bladder biopsy and urine cytology.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>24 months</time_frame>
    <description>For phase IIb patients in Cohort B: compare disease-free survival between treatment arms using cystoscopy, confirmatory bladder biopsy and urine cytology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>For phase IIb, Cohorts A &amp; B: time from randomization to disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>For phase Ib and IIb: all enrolled patients will be followed for 2 years to determine survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease specific survival</measure>
    <time_frame>24 months</time_frame>
    <description>For phase IIb, Cohorts A &amp; B: time from randomization to death resulting from bladder cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease worsening</measure>
    <time_frame>24 months</time_frame>
    <description>For phase IIb, Cohorts A &amp; B: cystectomy or change in therapy indicative of more advanced disease, including systemic chemotherapy or radiation therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to cystectomy</measure>
    <time_frame>24 months</time_frame>
    <description>For phase IIb, Cohorts A &amp; B: time from randomization to cystectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Profile: Number and severity of treatment related AEs</measure>
    <time_frame>48 months</time_frame>
    <description>For phase Ib and phase IIb Number and severity of treatment related AEs that occur or worsen after the first dose of study treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunogenicity: serum level of anti-ALT-803 in patient samples</measure>
    <time_frame>24 months</time_frame>
    <description>For phase Ib and IIb Measures the serum level of anti-ALT-803 in patient samples.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">596</enrollment>
  <condition>Non-muscle Invasive Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>ALT-803+BCG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Phase Ib and IIb) for BCG-naive patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCG alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(Phase IIb) for BCG-naive patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG+ALT-803</intervention_name>
    <description>BCG and ALT-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG+ALT-803 for 3 consecutive weeks at 3, 6, 12, &amp; 18 months.
An additional 6 week re-induction of BCG+ALT-803 for patients with eligible disease at 3 months in phase IIb is included.</description>
    <arm_group_label>ALT-803+BCG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG</intervention_name>
    <description>BCG will be administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG for 3 consecutive weeks at 3, 6, 12, &amp; 18 months.
An additional 6 week re-induction of BCG for patients with eligible disease at 3 months in phase IIb is included.</description>
    <arm_group_label>BCG alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Histologic confirmation of non-muscle invasive bladder cancer of the transitional cell
             carcinoma high-grade subtype (mixed histology tumors allowed if transitional cell
             histology is predominant histology).

               1. Cohort A: Histologically confirmed CIS (with or without Ta/T1 disease); Cohort B:
                  Histologically confirmed high-grade papillary disease (Ta/T1 only).

               2. Patients are eligible if the diagnostic biopsy was done within 3 months of
                  treatment start and a cystoscopy demonstrating no resectable disease was done
                  within 6 weeks of treatment start (residual CIS is acceptable; patients with T1
                  disease must undergo repeat resection if muscularis propria is not present in
                  each biopsy sample). Patients with high-grade Ta and/or T1 disease should have
                  complete resection before study treatment.

               3. Upper tract imaging within 6 months prior to study entry must not be suspicious
                  for upper tract malignancy.

          2. Currently eligible for intravesical BCG therapy.

          3. Age ≥ 18 years.

          4. Performance status: ECOG performance status of 0, 1, or 2.

          5. Laboratory tests performed within 21 days of treatment start:

               1. Absolute neutrophil count (AGC/ANC) ≥ 1,000/µL

               2. Platelets ≥ 100,000/µL [Patients may be transfused to meet this requirement]

               3. Hemoglobin ≥ 8 g/dL [Patients may be transfused to meet this requirement]

               4. Calculated glomerular filtration rate (GFR*) &gt;40 mL/min or Serum creatinine ≤ 1.5
                  x ULN

               5. Total bilirubin ≤ 2.0 X ULN

               6. AST, ALT, ALP ≤ 3.0 X ULN

          6. Adequate pulmonary function without any clinical sign of severe pulmonary dysfunction.
             PFT &gt; 50% FEV1 if clinically indicated by the investigator.

          7. Negative serum pregnancy test if female and of childbearing potential
             (non-childbearing is defined as greater than one year postmenopausal or surgically
             sterilized).

          8. Female participants of childbearing potential must adhere to using a medically
             accepted method of birth control prior to screening and agree to continue its use
             during the study or be surgically sterilized (e.g., hysterectomy or tubal ligation)
             and males must agree to use barrier methods of birth control while on study.

          9. Provide signed informed consent and HIPPA authorization and agree to comply with all
             protocol-specified procedures and follow-up evaluations.

               -  using the following Cockcroft-Gault equation to calculate the eGFR for this
                  study: eGFR in mL/min = {(140-age in years) x (weight in kg) x F}/(serum
                  creatinine in mg/dL x 72) Where F =1 if male; and 0.85 if female

        Exclusion Criteria

          1. Prior BCG treatment or known hypersensitivity to BCG. Patients who have received more
             than a single-dose post-operative treatment of mitomycin-C or gemcitabine are
             excluded.

          2. Concurrent use of other investigational agents.

          3. History of or evidence of muscle-invasive, locally advanced, metastatic and/or
             extravesical bladder cancer or any other cancer within the past 5 years, except:
             adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer,
             adequately treated stage 1 or 2 cancer from which the patient is currently in complete
             remission, or stable prostate cancer (under active surveillance or hormone control).

          4. Symptomatic congestive heart failure (CHF), NYHA (New York Heart Association) Class
             III or IV or other clinical signs of severe cardiac dysfunction.

          5. Severe/unstable angina pectoris, or myocardial infarction within 6 months prior to
             study entry.

          6. History or evidence of uncontrollable CNS disease.

          7. Known HIV-positive.

          8. Active systemic infection requiring parenteral antibiotic therapy. All prior
             infections must have resolved following optimal therapy.

          9. Concurrent febrile illness, active urinary tract infection, active tuberculosis, a
             history of hypotension or anaphylactic reactions.

         10. Ongoing chronic systemic steroid therapy required (&gt;10 mg oral prednisone daily or
             equivalent).

         11. Women who are pregnant or nursing. Female patients of childbearing potential must have
             a negative pregnancy test and must adhere to using a medically acceptable method of
             birth control prior to screening and agree to continue its use during the study and
             for 30 days after the last dose of study drug, or be surgically sterilized (e.g.,
             hysterectomy or tubal ligation). Women of childbearing potential are defined as any
             female who has experienced menarche and who is NOT permanently sterile or
             postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses
             without an alternative medical cause. Males must agree to use barrier methods of birth
             control while on study and for 90 days post last dose of study drug.

         12. Psychiatric illness/social situations that would limit compliance with study
             requirements.

         13. Other illness that in the opinion of the investigator would exclude the patient from
             participating in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Rock, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Altor BioScience</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Hui, MPH, MBA</last_name>
    <phone>(954) 443-8600</phone>
    <phone_ext>888</phone_ext>
    <email>emily.hui@immunitybio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liza H Ochoa</last_name>
    <phone>(954) 443-8600</phone>
    <phone_ext>879</phone_ext>
    <email>liza.hochoa@immunitybio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alaska Clinical Research Center</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Chriswell</last_name>
      <email>achriswell@akmed.com</email>
    </contact>
    <investigator>
      <last_name>William R Clark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Urology</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie O'Brien</last_name>
      <phone>501-219-8900</phone>
      <phone_ext>2002</phone_ext>
      <email>katie@arkansasurology.com</email>
    </contact>
    <investigator>
      <last_name>Richard D'Anna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Department of Urology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ankush Sachdeva</last_name>
      <phone>310-794-3512</phone>
      <email>asachdeva@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sara Rodriguez</last_name>
      <email>SaraRodriguez@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Karim Chamie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skyline Sherman Oaks</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skyline Urology</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eastern Connecticut Hematology &amp; Oncology Associates</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Florida</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jack Herman</last_name>
      <email>jack@floridacrc.com</email>
    </contact>
    <investigator>
      <last_name>Steven Kester, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Austin Lannon</last_name>
      <email>Austin.Lannon@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Wade Sexton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Hawaii Cancer Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veena Ramakrishna</last_name>
      <phone>313-576-9703</phone>
      <email>ramakriv@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Michael L Cher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adult &amp; Pediatric Urology</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayla Bowles</last_name>
      <phone>402-397-7989</phone>
      <email>kbowles@adultpediatricuro.com</email>
    </contact>
    <investigator>
      <last_name>Andrew Trainer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Esancy</last_name>
      <email>Charlotte.A.Esancy@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Einar F Sverrisson, MB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology Group of New Mexico (AccumetRx Clinical Research)</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ethan Contreras</last_name>
      <phone>505-872-4091</phone>
      <phone_ext>118</phone_ext>
      <email>econtreras@accumetrx.com</email>
    </contact>
    <investigator>
      <last_name>Frederick Snoy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saila Khan</last_name>
      <email>Saila.Khan@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Aaron E Katz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manhattan Medical Research</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmela Graci-Pipitone</last_name>
      <phone>917-409-3919</phone>
      <email>cgpipitone@manhattanmedicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group of the Hudson Valley</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Gray</last_name>
      <phone>845-437-5000</phone>
      <email>lgray@premiermedicalhv.com</email>
    </contact>
    <investigator>
      <last_name>Evan Goldfischer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associated Urologists of North Carolina</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kip Moffett</last_name>
      <email>kmoffett@auncurology.com</email>
    </contact>
    <investigator>
      <last_name>Mark Jalkut, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Urology</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Rose</last_name>
      <email>clrose@uro.com</email>
    </contact>
    <investigator>
      <last_name>Eugene Kramolowsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington School of Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2014</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antitumor</keyword>
  <keyword>BCG</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>cancer</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>instillation</keyword>
  <keyword>interleukin-15</keyword>
  <keyword>intravesical</keyword>
  <keyword>naive</keyword>
  <keyword>non-muscle invasive</keyword>
  <keyword>transitional cell carcinoma</keyword>
  <keyword>ALT-803</keyword>
  <keyword>N-803</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

